NRX leading biotech plays in 2024
NRX Nurexone Biologic leading biotech plays in 2024 with several recent developments from newly uplisting on the OTC, leasing agreement until 2028 of a state-of-the-art facility on a University campus in Israel to beginning clinical trials shortly. 
相關出版品
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。